Pharma

Your Article Summary

See Latest Articles

Phase III Study Showed Two Years of ACTEMRA Inhibited Progression of Joint Damage and Improved Disease Remission
Genentech, 10/19/09

Genentech, Inc., a wholly–owned member of the Roche Group, announced two–year results from a Phase III study, which showed that people with rheumatoid arthritis who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA, in combination with methotrexate, had no progression of joint damage, compared with people who received methotrexate alone. The overall safety profile of ACTEMRA was consistent across all global clinical studies.

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer MaterialScience invests in high-tech products for medical technology
BayNews International, 11/24/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

New Makrofol ID film system developed - Watermarks for polycarbonate cards
BayNews International, 11/24/09

 See all of Medical Devices/Products

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Innovative polyurethane spray systems for district cooling
BayNews International, 11/24/09

Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09

Prodesse's ProFlu-ST Assay Receives European CE Mark
Gen-Probe, 11/24/09

 See all of Research & Development